¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Naegeli type of monocytic leukaemia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hyperlipidemia type IV
    4Çü°íÁöÇ÷Áõ
  • hyperlipidemia type V
    5Çü°íÁöÇ÷Áõ
  • hypertrophic type
    ºñ´ëÇü
  • hebephrenic type schizophrenia
    ÆÄ°úÇüÁ¤½ÅºÐ¿­º´
  • hemispheric type
    ¹Ý±¸Çü
  • hemochorial type
    À¶Ç÷¸ðÇü
  • introversion type
    ³»ÇâÇü
  • intuitive type
    Á÷°üÇü
  • linear type constitution
    ¼±ÇüüÇü
  • mating type
    ±³¹èÇü
  • meromyarian type
    ºÎºÐ±ÙÀ°Çü
  • nomenclatural type
    ºÐ·ùÇÐÀû±âÁظí
  • organic reaction type
    ±âÁú¹ÝÀÀÇü
  • ovulatory type
    ¹è¶õÇü
  • polymyarian type
    ´Ù±ÙÀ°Çü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • type culture collection
    Ç¥ÁرÕÁÖ¼ö·Ï
  • delayed-type hypersensitivity
    Áö¿¬°ú¹Î
  • disorganized type schizophrenia
    ºØ±«Á¤½ÅºÐ¿­º´
  • dromedary type
    ´ÜºÀÇü
  • dysplastic type
    Çü¼ºÀÌ»óÇü
  • expansive type
    °ú´ëÇü
  • extroverted type
    ¿ÜÇâÇü
  • extroverted feeling type
    ¿ÜÇâÀû°¨Á¤Çü
  • Golgi type I neuron
    ±äÃà»è½Å°æ¼¼Æ÷
  • Golgi type II neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
  • hebephrenic type schizophrenia
    ÆÄ°úÁ¤½ÅºÐ¿­º´
  • hemispheric type
    ¹Ý±¸Çü
  • hemochorial type
    À¶Ç÷¸ðÇü
  • holomyarian type
    ¿ÏÀü±ÙÀ°Çü
  • hypertrophic type
    ºñ´ëÇü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Ogawa type
    ¿À°¡¿ÍÇü
  • RF coil type
    °íÁÖÆÄ ÄÚÀÏ À¯Çü
  • T-type channel
    T-Çü Åë·Î
  • aberrant type
    ÀÌÇü(ì¶úþ)
  • abortive type
    ºÎÀüÇü(ÝÕîïúþ).
  • acute fulminating type
    ±Þ¼º Àü°ÝÇü.
  • agammaglobulinemia,x-linked, bruton type
    ¼º¿°»öü ¿¬°ü¼º, ºê·çÅæÇü(àõæøßäô÷ æáμàõ, ¡­úþ)
  • anovulatory type
    ¹«¹è¶õÇü
  • glomus type of arteriovenous anastomosis
    Å丮Çüµ¿Á¤¸Æ¿¬°á
  • golgi type i neuron
    ±äÃà»è½Å°æ¼¼Æ÷
  • golgi type ii neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
  • growth onset type diabetes
    Ãʱâ´ç´¢º´.
  • hebephrenic type
    ÆÄ°úÇü(÷òÍþúþ)
  • hemochorial type
    À¶Ç÷¸ðÇü(ëÖúìÙ¾úþ).
  • hemoglobin C type
    CÇü Ç÷»ö¼Ò
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acute fulminating type
    ±Þ¼º Àü°ÝÇü.
  • agammaglobulinemia,x-linked, bruton type
    ¼º¿°»öü ¿¬°ü¼º, ºê·çÅæÇü(àõæøßäô÷ æáμàõ, ¡­úþ)
  • anovulatory type
    ¹«¹è¶õÇü
  • association type
    ¿¬»óÀ¯Çü
  • asthenia type
    ¹«·ÂüÇü.
  • atypical type
    ºñÁ¤Çü ÇüÅÂ
  • bell type
    Á¾¸ð¾ç, Á¾Çü.
  • blood group =b. type
    Ç÷¾×Çü(Ì´ËâÌ´).
  • blood group =b. type
    Ç÷¾×Çü(úìäûû¡).
  • blood type
    Ç÷¾×Çü(Ì´ËâÌ´).
  • blood type
    Ç÷¾×Çü(úìäûúþ)
  • body type
    üÇü
  • body type
    üÇü(ô÷úþ).
  • bubble type vaporizer
    ±âÆ÷Çü ±âÈ­±â
  • calcified hypertrophic type
    ¼®È¸È­ºñ´ëÇü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Glomus type of arteriovenous anastomosis
    Å丮Çüµ¿Á¤¸Æ¿¬°á
    [¿¾ ¿ë¾î] ±¸Çüµ¿Á¤¸Æ¹®ÇÕ
  • Mixed type of artery
    È¥ÇÕÇüµ¿¸Æ
    [¿¾ ¿ë¾î] È¥ÇÕÇüµ¿¸Æ
  • Chief cell [Type I glomus cell]
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁÖ¼¼Æ÷
  • Pneumocyte type II
    °ú¸³ÇãÆÄ²Ê¸®¼¼Æ÷
    [¿¾ ¿ë¾î] ´ëÆóÆ÷¼¼Æ÷
  • Golgi type I neuron
    ±äÃà»è½Å°æ¼¼Æ÷
    [¿¾ ¿ë¾î] ÀåÃà»è´Ù±Ø½Å°æ¿ø
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷(Á¦2Çü»ç±¸¼¼Æ÷)
  • Hypertrophic type
    ºñ´ëÇü
    [¿¾ ¿ë¾î] ºñ´ëÇü
  • Fibrous type of vein
    ¼¶À¯ÇüÁ¤¸Æ
    [¿¾ ¿ë¾î] ¼¶À¯ÇüÁ¤¸Æ
  • Golgi type II neuron
    ªÀºÃà»è½Å°æ¼¼Æ÷
    [¿¾ ¿ë¾î] ´ÜÃà»è´Ù±Ø½Å°æ¿ø
  • Pneumocyte type I
    È£ÈíÇãÆÄ²Ê¸®¼¼Æ÷
    [¿¾ ¿ë¾î] È£Èí»óÇǼ¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • type C virus
    CÇü(úþ) ¹ÙÀÌ·¯½º
  • type C RNA virus
    CÇü(úþ) RNA ¹ÙÀÌ·¯½º
  • type I error
    IÇü(úþ) ¿ÀÂ÷(è¦ó¬)
  • type II error
    IIÇü(úþ) ¿ÀÂ÷(è¦ó¬)
  • type I immunoglobulin
    IÇü(úþ) ¸é¿ª(Øóæ¹)±Û·ÎºÒ¸°
  • type II immunoglobulin
    IIÇü(úþ) ¸é¿ª(Øóæ¹)±Û·ÎºÒ¸°
  • type K immunoglobulin
    KÇü(úþ) ¸é¿ª(Øóæ¹) ±Û·ÎºÒ¸°
  • type L immunoglobulin
    LÇü(úþ) ¸é¿ª(Øóæ¹)±Û·ÎºÒ¸°
  • type-specific antigen
    ÇüƯÀÌ Ç׿ø(úþ÷åì¶ù÷ê«)
  • Watson-Crick-type DNA
    ¿Ó½¼-Å©¸¯Çü(úþ) DNA
  • wild-type
    ¾ß»ýÇü(å¯ßæúþ)
  • wild-type allele
    ¾ß»ýÇü(å¯ßæúþ) ´ë¸³(Óߨ¡)À¯ÀüÀÚ(ë¶îîí­)
  • wild-type gene
    ¾ß»ýÇü(å¯ßæúþ) À¯ÀüÀÚ(ë¶îîí­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
AML Acute Myelogenous Leukemia
  Morphologic Classification(FABºÐ·ù)
   &n...
CMML Chronic Myelo-Monocytic Leukemia
AML acute monocytic leukemia; acute mucosal lesion; acute myeloblastic leukemia; acute myelocytic leukem...
CMOL chronic monocytic leukemia
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
B-CLL B type chronic lymphocytic leukaemia
HTLV1 Human T cell Leukaemia Virus Type 1
HTLV-I Human T cell leukaemia virus type I
HTLV-III Human T-cell leukaemia virus type III
HSV-2 Herpes Simplex Virus type I and type 2
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • delayed-type hyperseneitivity
    Áö¿¬Çü °ú¹ÎÁõ
    °¨ÀÛµÈ T ¸²ÇÁ±¸¿¡ ÀÇÇÏ¿© Àü´ÞµÇ´Â °ú¹ÎÁõ. Ç×ü¿¡ ÀÇÇÏ¿© ¹ß»ýÇÏ´Â °ú¹ÎÁõÀÌ ¾Æ´Ï°í º¸Åë ¸²ÇÁ±¸¿Í macro
  • Diego blood type
    µð¿¡°í½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ Çϳª. 1954³â º£³×¼ö¿¤¶óÀÇ µð¿¡°í°¡¿¡¼­ ½Å»ý¾Æ ¿ëÇ÷¼º Áúȯ ȯÀÚÀÇ ¾î¸Ó´Ï Ç÷û¿¡¼­ Ç×ü°¡, ¾Æ¹öÁö¿¡°Ô¼­´Â Ç׿øÀÌ ¹ß°ßµÇ¾ú´Ù. Di Ç×ü¿¡ ´ëÇØ ÀûÇ÷±¸°¡ ÀÀÁý ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â °ÍÀ» Di
  • distal step type
    ¿ø½É °è´ÜÇü
  • Dombrock blood type
    µ¼ºê·Ï½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ Çϳª. »ç¶÷ÀÇ Ç÷±¸ °¡¿îµ¥ Ç×Do Ç×ü¿Í ÀÀÁý ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Do
  • dorsolumbal type
    Èä¿äºÎ Çü, ¹èÃø ¿äºÎ Çü
  • dysplastic type
    ¹ßÀ° ºÎÀü ü°Ý
  • epidermoid type cell
    À¯Ç¥ÇÇ ¼¼Æ÷
  • ferm-type design
    ¾çÄ¡·ù ÇüÅÂÀÇ µðÀÚÀÎ
  • herpes simplex virus type 1
    Á¦1Çü ´Ü¼ø Æ÷Áø ¹ÙÀÌ·¯½º
  • herpes type I vaccine
    Á¦1Çü Æ÷Áø ¹é½Å
  • hinge type
    °æÃ¸Çü
    ÇϾǰñ ¿îµ¿.Áß ´Ü¼øÈ÷ °³±¸ ¶Ç´Â Æó±¸.¿îµ¿¸¸ ÇÏ´Â ÇüÅÂ.
  • HL-A type antigen
    ¿¡ÀÌÄ¡¿¤¿¡ÀÌ Ç׿ø
    »ç¶÷ÀÇ ÀûÇ÷±¸ ÀÌ¿ÜÀÇ ¸ðµç ¼¼Æ÷°¡ °¡Áö°í ÀÖ´Â Ç׿ø. »ç¶÷ ¹éÇ÷±¸ Ç׿øÀ̶ó°íµµ ÇÑ´Ù. H´Â »ç¶÷
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • hutchinson-type neuroblastoma
    ÇãÄ£½¼Çü ½Å°æ¸ð¼¼Æ÷Á¾
  • hypocalcified type
    ¼®È¸È­ ºÎÀüÇü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
acute leukaemia <haematology> A rapidly progressive cancer of the blood of sudden onset and characterised by the uncontrolled proliferation of immature blood cells which take over the bone marrow and spill into the blood stream. If left untreated is fatal within a few weeks or months.
See: acute lymphoblastic leukaemia, acute myeloid leukaemia.
Origin: Gr. Haima = blood
(11 Nov 1997)
acute lymphoblastic leukaemia <haematology> A rapidly progressing cancer of the blood affecting the type of white blood cell known as lymphocytes. Approximately 650 new cases are diagnosed every year in the UK and it is the most common form of childhood leukaemia.
Acronym: ALL
Origin: Gr. Haima = blood
(11 Nov 1997)
acute lymphocytic leukaemia <radiology> 95% of cases of leukaemia in children, bone changes in 50-70% of kids (vs. 10% in adults); seen as early as 1 month after onset of symptoms, wrists and knees most commonly affected, bony defects: metaphyseal radiolucent bands! (similar findings in scurvy, JRA, syphilis), osteolytic lesions, periosteal reaction, osteosclerosis
(12 Dec 1998)
acute myeloblastic leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myelogenous leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myeloid leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute non-lymphocytic leukaemia <haematology> A form of leukaemia which is characterised by the proliferation of immature bone marrow precursor cells in the marrow and immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Trisomy-8 is the most common cytogenetic abnormality observed, followed by monosomy-7 and monosomy-5. Approximately 8% of cases show trisomy-8, mostly in AML (M1), AM (M4) and acute monocytic leukaemia (M5). Many pre-leukaemic conditions, acute non-lymphocytic leukaemia and secondary leukemia show monosomy-7 or deletion of the long arm of chromosome 7.
Treatment includes chemotherapy and/or bone marrow transplant.
Acronym: ANLL
Incidence: 2.5 cases per 100,000 (all ages).
Origin: Gr. Haima = blood
(07 Apr 1998)
acute promyelocytic leukaemia Leukaemia presenting as a severe bleeding disorder, with infiltration of the bone marrow by abnormal promyelocytes and myelocytes, a low plasma fibrinogen, and defective coagulation.
(05 Mar 2000)
adult T-cell leukaemia Lymph nodes show a mixture of small and large atypical cells which are polymorphic and express nuclear pleiomorphism. Adult T-cell leukaemia is caused by HTLV-1 and is rare in the US and Europe but common in Japan. Tumour cells express CD2, CD3, CD5 and lack CD7. The most common chromosome change reported in adult T-cell leukaemia is presence of the 14q + marker
(05 Mar 2000)
aleukaemic leukaemia Leukaemia in which abnormal (or leukaemic) cells are absent in the peripheral blood.
(05 Mar 2000)
avian leukaemia-sarcoma complex A term applied to a group of transmissible virus-induced diseases of chickens causing sarcoma, myeloblastosis, erythroblastosis, leukosis, osteopetrosis, and lymphomatosis. These agents are closely related viruses (avian leukosis-sarcoma virus) causing prolferation of immature erythroid, myeloid, or lymphoid cells, a division of the RNA tumour viruses (subfamily Oncovirinae) causing the avian leukosis-sarcoma complex of diseases; the viruses are subgrouped according to antigenic characteristics and growth in defined types of tissue culture cells.
Synonym: avian erythroblastosis virus, avian leukosis-sarcoma virus, avian lymphomatosis virus, avian myeloblastosis virus, avian sarcoma virus, fowl erythroblastosis virus, fowl lymphomatosis virus, fowl myeloblastosis virus.
(05 Mar 2000)
avian leukaemia virus <virology> Group of C type RNA tumour viruses (Oncovirinae) that cause various leukaemias and other tumours in birds.
The acute leukaemia viruses, that are replication defective and require helper viruses, include avian erythroblastosis (AEV), myeloblastosis (AMV) and myelo cytomatosis viruses.
AEV carries two transforming genes, v erbA and v erbB, the cellular homologue of the latter is the structural gene for the epidermal growth factor receptor. AMV carries v myb and causes a myeloid leukaemia, avian myelocytomatosis virus carries v myc.
The avian lymphatic leukaemia viruses (ALV) are also Retroviridae but are replication competent and induce neoplasia only after several months, they often occur in conjunction with replication defective leukaemia viruses.
(02 Jan 1998)
basophilic leukaemia A form of granulocytic leukaemia in which there are unusually great numbers of basophilic granulocytes in the tissues and circulating blood; in some instances, the immature and mature basophilic forms may represent from 40 to 80% of the total numbers of white blood cells.
Synonym: mast cell leukaemia.
(05 Mar 2000)
B-cell leukaemia A test which detects the presence of antigens on the surface of B lymphocytes. These antigens can indicate the presence of leukaemia. most often this is used to detect and differentiate chronic lymphocytic leukaemia from acute lymphocytic leukaemia.
Origin: Gr. Haima = blood
(27 Sep 1997)
bovine leukaemia A lymphoid neoplastic disease in cattle caused by the bovine leukaemia virus. Enzootic bovine leukosis may take the form of lymphosarcoma, malignant lymphoma, or leukaemia but the presence of malignant cells in the blood is not a consistent finding.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • moon type
    (¸ÍÀοëÀÇ)¹®½Ä¼±ÀÚ
  • repulsive(-type) maglev
    ¹Ý¹ß½Ä Àڱ⠺λó(Â÷ü¸¦ ¶ß°ÔÇϱâ À§ÇØ ÀüÀÚ¼®ÀÇ ¹Ý¹ß·ÂÀ» ÀÌ¿ë)
  • type
    Çü;À¯Çü;¾ç½Ä;ÀüÇü;°ßº»;Ç¥;ȰÀÚ;Ç÷¾×Çü;in ~ ȰÀڷΠ§(Â¥¼­);set ~ Á¶ÆÇÇÏ´Ù
  • type
    ŸÀÌÇÁ¶óÀÌÅÍ·Î Âï´Ù;(Ç÷¾×)ÇüÀ» °Ë»çÇÏ´Ù;»ó¡ÇÏ´Ù;...ÀÇ ÀüÇüÀÌ µÇ´Ù
  • type cast
    (±ØÁß Àι°ÀÇ ½ÅÀå,¸ñ¼Ò¸® µûÀ§¿¡ ¸Â´Â) ¹è¿ì¸¦ ¹è¿ªÇÏ´Ù
  • type founder
    ȰÀÚ ÁÖÁ¶°ø(¾÷ÀÚ)
  • type metal
    ȰÀÚ ÇÕ±Ý
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á